JP6861634B2 - 眼疾患を処置するための組成物及び方法 - Google Patents

眼疾患を処置するための組成物及び方法 Download PDF

Info

Publication number
JP6861634B2
JP6861634B2 JP2017545950A JP2017545950A JP6861634B2 JP 6861634 B2 JP6861634 B2 JP 6861634B2 JP 2017545950 A JP2017545950 A JP 2017545950A JP 2017545950 A JP2017545950 A JP 2017545950A JP 6861634 B2 JP6861634 B2 JP 6861634B2
Authority
JP
Japan
Prior art keywords
group
composition according
composition
eye
spironolactone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017545950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510855A5 (https=
JP2018510855A (ja
Inventor
イー，リチャード，ダブリュ．
ヒューズ，ケネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018510855A publication Critical patent/JP2018510855A/ja
Publication of JP2018510855A5 publication Critical patent/JP2018510855A5/ja
Application granted granted Critical
Publication of JP6861634B2 publication Critical patent/JP6861634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017545950A 2015-03-03 2016-03-03 眼疾患を処置するための組成物及び方法 Active JP6861634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562127362P 2015-03-03 2015-03-03
US62/127,362 2015-03-03
PCT/US2016/020683 WO2016141182A1 (en) 2015-03-03 2016-03-03 Compositions and methods for treating ocular diseases

Publications (3)

Publication Number Publication Date
JP2018510855A JP2018510855A (ja) 2018-04-19
JP2018510855A5 JP2018510855A5 (https=) 2019-04-11
JP6861634B2 true JP6861634B2 (ja) 2021-04-21

Family

ID=56848617

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017545950A Active JP6861634B2 (ja) 2015-03-03 2016-03-03 眼疾患を処置するための組成物及び方法

Country Status (5)

Country Link
US (1) US10350223B2 (https=)
EP (1) EP3265103B1 (https=)
JP (1) JP6861634B2 (https=)
ES (1) ES2984281T3 (https=)
WO (1) WO2016141182A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140207A1 (en) * 2018-01-11 2019-07-18 Yee Richard W Compositions and methods for treating ocular diseases
US12161752B2 (en) * 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
CN113577022B (zh) * 2021-05-18 2023-03-17 南京欣通瑞亿医药科技有限公司 一种氨苯砜类化合物混悬液及其制备方法和应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551554A (en) 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4192802A (en) 1976-06-09 1980-03-11 Ciba-Geigy Corporation Process for the manufacture of steroid carboxylic acid lactones
FI59534C (fi) 1979-10-31 1981-09-10 Orion Yhtymae Oy Vaordmedel foer fraemjande av haorvaext och hindrande av mjaell
GR74635B (https=) 1980-08-18 1984-06-29 Merck & Co Inc
USRE32112E (en) 1981-05-26 1986-04-15 Spironolactone-containing composition and use thereof
IT1194185B (it) 1983-04-01 1988-09-14 Schiapparelli Farma Composizione per il trattamento dell'acne
ES532317A0 (es) 1983-05-16 1985-11-16 Merck & Co Inc Una composicion farmaceutica
FR2588755B3 (fr) 1985-10-21 1988-01-22 Aron Brunetiere Robert Composition therapeutique a base de spironolactone destinee au traitement des alopecies androgenogenetiques
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
EP0410348A1 (en) 1989-07-26 1991-01-30 G.D. Searle & Co. Topical spironolactone composition
JPH05331066A (ja) 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
MX9303557A (es) 1992-08-06 1994-03-31 Beta Pharm Co Metodo para la administracion de un antiandrogeno, en particular, espironolactona, a traves de la piel.
WO1996040258A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
ATE343379T1 (de) 1998-08-20 2006-11-15 3M Innovative Properties Co Sprühverband und wirkstoffabgabesystem
AU5460800A (en) 1999-06-02 2000-12-18 Aviana Biopharm Pharmaceutical transdermal compositions
EP1227804B1 (en) 1999-11-09 2007-08-22 Pharmacia Corporation Use of eplerenone for treating restenosis
WO2003049745A1 (en) 2001-12-12 2003-06-19 Pharmacia Corporation Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
PL371437A1 (en) 2002-01-30 2005-06-13 Pharmacia Corporation Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
CL2004000574A1 (es) 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2006002022A2 (en) 2004-06-15 2006-01-05 Immusol Incorporated Compositions and methods useful for the treatment of hyperglycemia
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
JP4969052B2 (ja) 2005-03-31 2012-07-04 小林製薬株式会社 眼科用組成物
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
GB0615064D0 (en) 2006-07-28 2006-09-06 Sinclair Pharmaceuticals Ltd Medicament
US7879910B1 (en) 2006-10-10 2011-02-01 Jan Marini Skin Research, Inc. Compositions and methods for promoting lush hair growth
US20100068301A1 (en) 2006-11-30 2010-03-18 Hutchinson John H Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
EP3574909B1 (en) 2008-01-30 2026-03-04 Imbed Biosciences, Inc. Polyelectrolyte multilayer comprising silver for wound healing
US8318678B2 (en) 2008-05-30 2012-11-27 Jan Marini Skin Research Cosmetic compositions
US20090325918A1 (en) 2008-06-16 2009-12-31 Somberg John C Synthesis and separation of optically active isomers and cyclopropyl derivatives of spironolactone and their biological action
WO2010038234A1 (en) 2008-10-02 2010-04-08 Taro Pharmaceutical Industries Ltd. Combination product of spironolactone and doxycycline
WO2010096558A1 (en) 2009-02-18 2010-08-26 Eyeon Particle Sciences Llc Bi-functional co-polymer use for ophthalmic and other topical and local applications
CA2769041A1 (en) 2009-07-18 2011-01-27 Leuko Ophthalmic Technologies Limited Methods material and systems for producing a contact lens and contact lenses produced using said methods material and systems
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
US20120252756A1 (en) * 2010-06-25 2012-10-04 Coffey Martin J Pharmaceutical Compositions and Methods for Treating, Controlling, Ameliorating, or Reversing Conditions of the Eye
WO2012093117A1 (en) 2011-01-03 2012-07-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US9808529B2 (en) 2012-05-18 2017-11-07 Luoda Pharma Pty Ltd Liquid formulation
WO2014202744A1 (en) 2013-06-21 2014-12-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning

Also Published As

Publication number Publication date
US20180050049A1 (en) 2018-02-22
EP3265103A1 (en) 2018-01-10
EP3265103C0 (en) 2024-07-24
EP3265103A4 (en) 2018-11-14
ES2984281T3 (es) 2024-10-29
EP3265103B1 (en) 2024-07-24
US10350223B2 (en) 2019-07-16
JP2018510855A (ja) 2018-04-19
WO2016141182A1 (en) 2016-09-09

Similar Documents

Publication Publication Date Title
Thode et al. Current and emerging therapeutic strategies for the treatment of meibomian gland dysfunction (MGD)
JP6209777B2 (ja) 眼の疾病及び疾患のための組成物及び治療
JP7844532B2 (ja) ポリアフロンおよびその眼瞼投与
EA019867B1 (ru) Водные офтальмологические препараты
JP2011515494A (ja) テトラサイクリンファミリー抗生物質を用いる、眼瞼縁および涙液膜機能の改善ならびに眼瞼縁疾患の処置のための方法
AU2011334617B2 (en) Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions
KR20090104813A (ko) 안구건조증의 치료
CN110177556A (zh) 含有熊去氧胆酸的用于预防或治疗视力障碍的组合物
WO2011159632A1 (en) Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
JP6861634B2 (ja) 眼疾患を処置するための組成物及び方法
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
US20190328753A1 (en) Compositions and methods for treating ocular diseases
CN111655262A (zh) 用于预防和治疗病症的组合物及方法
TWI868659B (zh) 無防腐劑的眼科藥物乳劑及其應用
TWI918632B (zh) 黃體激素組合
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
TW201028176A (en) Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
CA3076567C (en) Ophthalmic compositions comprising f6h8
WO2019140207A1 (en) Compositions and methods for treating ocular diseases
US20240009124A1 (en) Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
WO2026058289A1 (en) Ophthalmic composition of dexamethasone
WO2021163253A1 (en) Progesterone combinations
Garrigue et al. A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models
JP2009114153A (ja) トラニラストゲル状懸濁剤
Roopadevi A Comparative Study of Efficacy and Safety of Difluprednate Ophthalmic Emulsion 0.05% with Prednisolone Acetate Ophthalmic Suspension 1% for Managing Ocular Inflammation and Pain Following Cataract Surgery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210330

R150 Certificate of patent or registration of utility model

Ref document number: 6861634

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250